New pill aims to tame irregular heartbeat in atrial fibrillation patients

NCT ID NCT07217067

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This Phase 2 trial tests an oral drug called PKN605 in 165 adults with atrial fibrillation. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doctors know which they get. The main goal is to see if PKN605 reduces the amount of time spent in atrial fibrillation, as measured by ECG patch monitors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PKN605 (oral drug)
What this could lead to: If it works, this could lead to a new daily pill that helps control atrial fibrillation and reduces the time spent in irregular heart rhythm.
What could go wrong: This is an early Phase 2 trial with only 165 participants, so results may not apply to everyone. The drug may not reduce AF burden more than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Cardiology Associates of North MS
RECRUITING

Tupelo, Mississippi, 38801, United States
Cooper University Hospital
RECRUITING

Camden, New Jersey, 08103, United States
Duke Univ Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Intermountain Medical Center
RECRUITING

Murray, Utah, 84107, United States
Novartis Investigative Site
RECRUITING

Calgary, Alberta, T2P 3C5, Canada
Novartis Investigative Site
RECRUITING

Vancouver, British Columbia, V5Z 1M9, Canada
Novartis Investigative Site
RECRUITING

Halifax, Nova Scotia, B3H 3A7, Canada
Novartis Investigative Site
RECRUITING

Hamilton, Ontario, L8L 2X2, Canada
Novartis Investigative Site
RECRUITING

London, Ontario, N6A 5W9, Canada
Novartis Investigative Site
RECRUITING

Newmarket, Ontario, L3Y 2P6, Canada
Novartis Investigative Site
RECRUITING

Toronto, Ontario, M4N 3M5, Canada
Novartis Investigative Site
RECRUITING

Toronto, Ontario, M5B 1W8, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H1T 1C8, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H2X 1R9, Canada
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Novartis Investigative Site
RECRUITING

Québec, Quebec, G1V 4G5, Canada
Novartis Investigative Site
RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
Novartis Investigative Site
RECRUITING

Beijing, Beijing Municipality, 100013, China
Novartis Investigative Site
RECRUITING

Beijing, 100730, China
Novartis Investigative Site
RECRUITING

Xi'an, 223001, China
Novartis Investigative Site
RECRUITING

Bad Homburg, 61348, Germany
Novartis Investigative Site
RECRUITING

Berlin, 10787, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13353, Germany
Novartis Investigative Site
RECRUITING

Hamburg, 20099, Germany
Novartis Investigative Site
RECRUITING

Hamburg, 20246, Germany
Novartis Investigative Site
RECRUITING

Arnhem, Gelderland, 6815 AD, Netherlands
Novartis Investigative Site
RECRUITING

Maastricht, Limburg, 6229 HX, Netherlands
Novartis Investigative Site
RECRUITING

Delft, South Holland, 2625 AD, Netherlands
Novartis Investigative Site
RECRUITING

Goes, Zeeland, 4462 RA, Netherlands
Novartis Investigative Site
RECRUITING

Groningen, 9713 GZ, Netherlands
Novartis Investigative Site
RECRUITING

Veldhoven, 5504 DB, Netherlands
Novartis Investigative Site
RECRUITING

Singapore, Singapore, S308433, Singapore
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore
Novartis Investigative Site
RECRUITING

Singapore, 169609, Singapore
Novartis Investigative Site
RECRUITING

Brighton, East Sussex, BN2 5BE, United Kingdom
Novartis Investigative Site
RECRUITING

Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
Novartis Investigative Site
WITHDRAWN

Liverpool, L14 3PE, United Kingdom
Novartis Investigative Site
RECRUITING

London, W12 0HS, United Kingdom
Swedish Heart and Vascular Clinic
RECRUITING

Seattle, Washington, 98122, United States
Weill Cornell Medical Center
RECRUITING

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.